Sandoz Debuts US Combigan Rival
Follows Apotex Launch Of Authorized Generic Earlier This Year
Sandoz has expanded its ophthalmic portfolio with the introduction of the first US generic rival to Combigan. However, the firm will have to contend with an authorized generic launched earlier this year by Apotex.
You may also be interested in...
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
A US district court was right to bar Sandoz launching a generic version of Allergan’s Combigan glaucoma treatment due to limiting safety and efficacy clauses in three patents, the US Court of Appeals has confirmed.
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.